| __timestamp | Alnylam Pharmaceuticals, Inc. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 2242216 |
| Thursday, January 1, 2015 | 276495000 | 4536244 |
| Friday, January 1, 2016 | 382392000 | 5184803 |
| Sunday, January 1, 2017 | 390635000 | 3068742 |
| Monday, January 1, 2018 | 505420000 | 7178000 |
| Tuesday, January 1, 2019 | 655114000 | 16267000 |
| Wednesday, January 1, 2020 | 654819000 | 23191000 |
| Friday, January 1, 2021 | 792156000 | 21453000 |
| Saturday, January 1, 2022 | 883015000 | 15265000 |
| Sunday, January 1, 2023 | 1004415000 | 25189000 |
| Monday, January 1, 2024 | 1126232000 |
Unlocking the unknown
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Alnylam Pharmaceuticals, Inc. and Soleno Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment.
Since 2014, Alnylam Pharmaceuticals has consistently increased its R&D expenses, reflecting a robust commitment to pioneering new therapies. By 2023, their R&D spending surged by over 400%, reaching a peak of approximately $1 billion. This growth underscores Alnylam's strategic focus on expanding its therapeutic pipeline and maintaining its leadership in RNA interference technology.
In contrast, Soleno Therapeutics has shown a more modest increase in R&D spending, with a tenfold rise from 2014 to 2023. Despite a smaller budget, Soleno's targeted investments highlight its dedication to developing treatments for rare diseases, showcasing a focused yet impactful approach to innovation.
Analyzing R&D Budgets: Sanofi vs Soleno Therapeutics, Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and United Therapeutics Corporation
R&D Insights: How Alnylam Pharmaceuticals, Inc. and Intra-Cellular Therapies, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Incyte Corporation
Research and Development: Comparing Key Metrics for Alnylam Pharmaceuticals, Inc. and Exelixis, Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Opthea Limited
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Amneal Pharmaceuticals, Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Xencor, Inc.
Research and Development Expenses Breakdown: MorphoSys AG vs Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Soleno Therapeutics, Inc. and Wave Life Sciences Ltd.